Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
One of the first projects to be selected for funding under the European Innovative Medicines Initiative will address the challenges of developing drugs to treat schizophrenia and depression.
More effective prediction of 'translational success' could have a key role in addressing the widely acknowledged problems with weak drug development pipelines. This article discusses how establishing a scoring system to systematically assess key determinants of translational success, such as biomarkers and animal and human data, could help achieve this goal.
Aberrant activity of cell cycle protein kinases, leading to uncontrolled cell proliferation, is a hallmark of human cancer. Here, Lapenna and Giordano review recent progress in the modulation of specific protein kinase activity for the treatment of various cancers and identify novel strategies for the design of new agents.
Here, the authors summarize the current state of multi-parameter profiling technologies and how phenotypic profiling of small molecules provides important insights into their mechanisms of action, as well as a systems level understanding of biological pathways and their responses to drug treatments.
Drug resistance and the genomic instability of cancer cells hamper current gene-targeting therapeutic strategies for cancer. As Huang and colleagues discuss, targeting the unique biochemical properties of cancer cells — in particular, increased oxidative stress — might represent an alternative approach for the development of selective, redox-modulating anticancer agents.
